- Home
- BNZI vs LYRA Comparison
BNZI vs LYRA Comparison
Compare BNZI & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNZI
- LYRA
- Stock Information
- Founded
- BNZI 2016
- LYRA 2005
- Country
- BNZI United States
- LYRA United States
- Employees
- BNZI N/A
- LYRA N/A
- Industry
- BNZI
- LYRA Medical/Dental Instruments
- Sector
- BNZI
- LYRA Health Care
- Exchange
- BNZI Nasdaq
- LYRA Nasdaq
- Market Cap
- BNZI 11.5M
- LYRA 11.3M
- IPO Year
- BNZI N/A
- LYRA 2020
- Fundamental
- Price
- BNZI $2.13
- LYRA $6.41
- Analyst Decision
- BNZI Strong Buy
- LYRA Hold
- Analyst Count
- BNZI 1
- LYRA 1
- Target Price
- BNZI $240.00
- LYRA $16.00
- AVG Volume (30 Days)
- BNZI 330.9K
- LYRA 14.8K
- Earning Date
- BNZI 11-13-2025
- LYRA 11-11-2025
- Dividend Yield
- BNZI N/A
- LYRA N/A
- EPS Growth
- BNZI N/A
- LYRA N/A
- EPS
- BNZI N/A
- LYRA N/A
- Revenue
- BNZI $9,021,543.00
- LYRA $770,000.00
- Revenue This Year
- BNZI $337.60
- LYRA N/A
- Revenue Next Year
- BNZI $91.81
- LYRA $123.46
- P/E Ratio
- BNZI N/A
- LYRA N/A
- Revenue Growth
- BNZI 107.94
- LYRA N/A
- 52 Week Low
- BNZI $2.08
- LYRA $3.81
- 52 Week High
- BNZI $112.00
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- BNZI 30.58
- LYRA 38.58
- Support Level
- BNZI $2.08
- LYRA $6.15
- Resistance Level
- BNZI $2.68
- LYRA $6.72
- Average True Range (ATR)
- BNZI 0.23
- LYRA 0.38
- MACD
- BNZI -0.03
- LYRA -0.01
- Stochastic Oscillator
- BNZI 3.49
- LYRA 25.85
About BNZI Banzai International Inc.
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.